Ried, Michael, Eicher, Maria-Magdalena, Neu, Reiner, Sziklavari, Zsolt and Hofmann, Hans-Stefan
(2017)
Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival.
World Journal of Surgical Oncology 15 (1), pp. 1-8.
Date of publication of this fulltext: 29 Jan 2018 18:47at publisher (via DOI)
Other URL: http://doi.org/10.1186/s12957-017-1283-4, https://wjso.biomedcentral.com/articles/10.1186/s12957-017-1283-4
Dieser Artikel ist in einer Zeitschrift aus dem Directory of Open Access (DOAJ) publiziert.
Abstract
Background: The objective of this study is the evaluation of the Masaoka-Koga and the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposal for the new TNM-staging system on clinical implementation and prognosis of thymic malignancies. Methods: A retrospective study of 76 patients who underwent surgery between January 2005 ...
Abstract
Background: The objective of this study is the evaluation of the Masaoka-Koga and the International Association for the Study of Lung Cancer (IASLC)/International Thymic Malignancy Interest Group (ITMIG) proposal for the new TNM-staging system on clinical implementation and prognosis of thymic malignancies. Methods: A retrospective study of 76 patients who underwent surgery between January 2005 and December 2015 for thymoma. Kaplan-Meier survival analysis was used to determine overall and recurrence-free survival rates. Results: Indication for surgery was primary mediastinal tumor (n = 55), pleural manifestation (n = 17), or mediastinal recurrence (n = 4) after surgery for thymoma. Early Masaoka-Koga stages I (n = 9) and II (n = 14) shifted to the new stage I (n = 23). Advanced stages III (Masaoka-Koga: n = 20; ITMIG/IASLC: n = 17) and IV (Masaoka-Koga: n = 33; ITMIG/IASLC: n = 35) remained nearly similar and were associated with higher levels of WHO stages. Within each staging system, the survival curves differed significantly with the best 5-year survival in early stages I and II (91%). Survival for stage IV (70 to 77%) was significantly better compared to stage III (49 to 54%). Early stages had a significant longer recurrence-free survival (86 to 90%) than advanced stages III and IV (55 to 56%). Conclusions: The proportion of patients with IASLC/ITMIG stage I increased remarkably, whereas the distribution in advanced stages III and IV was nearly similar. The new TNM-staging system presents a clinically useful and applicable system, which can be used for indication, stage-adapted therapy, and prediction of prognosis for overall and recurrence-free survival.
Export bibliographical data
| Item type: | Article |
|---|
| Date: | 2 December 2017 |
|---|
| Institutions: | Medicine > Lehrstuhl für Unfallchirurgie |
|---|
| Projects: | Open Access Publizieren (DFG) |
|---|
| Identification Number: | | Value | Type |
|---|
| 10.1186/s12957-017-1283-4 | DOI |
|
|---|
| Keywords: | FORTHCOMING 8TH EDITION; LYMPH-NODE MAP; EPITHELIAL TUMORS; ADVANCED THYMOMA; INTERNATIONAL ASSOCIATION; PROGNOSTIC-FACTORS; PROJECT PROPOSALS; CLASSIFICATION; CARCINOMA; DATABASE; Thymoma; Thymic carcinoma; TNM staging; Masaoka-Koga; Staging system |
|---|
| Dewey Decimal Classification: | 600 Technology > 610 Medical sciences Medicine |
|---|
| Status: | Published |
|---|
| Refereed: | Yes, this version has been refereed |
|---|
| Created at the University of Regensburg: | Yes |
|---|
| Item ID: | 36650 |
|---|
Download Statistics